Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2012
Date:11/6/2012

CARLSBAD, Calif., Nov. 6, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $26.0 million and $36.0 million for the three and nine months ended September 30, 2012, respectively, compared to a pro forma NOL of $20.0 million and $44.9 million for the same periods in 2011. The Company ended the third quarter of 2012 with $343.6 million in cash. 

"We have had a very successful year. With a number of exciting events on the horizon, the remainder of 2012 promises to be equally eventful. Of course, the most notable events this year are associated with KYNAMRO™. We are pleased with the positive recommendation from the FDA's advisory committee for KYNAMRO and look forward to the FDA's decision early next year. We believe KYNAMRO could have a profound impact on the lives of patients with homozygous FH, who are at extreme cardiovascular risk and are in need of new therapeutic options. We look forward to bringing this important new medicine to these patients," said B. Lynne Parshall, Chief Operating Officer and Chief Financial Officer at Isis. 

"While KYNAMRO is the most notable of our successes, we have had many achievements across our pipeline. Most recently, we have completed key steps to move two of our severe and rare disease drugs toward commercial markets. We initiated the next clinical study in patients with spinal muscular atrophy for our drug, ISIS-SMNRx, which we partnered with Biogen Idec earlier this year. This study will be a relatively short study and will position us to initiate a registration-directed Phase 2/3 study next year. In addition, we and GSK amended the development plan for ISIS-TTRRx to employ a more efficient route to the market. We plan to initiate the Phase 2/3 study evaluating ISIS-TTRRx'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. MEI Pharma Reports New Data Showing High Response Rates in Clinical Trial of Pracinostat and Azacitidine in Myelodysplastic Syndrome
2. CVS Caremark Reports Third Quarter Results
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
4. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
5. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
6. Depomed Reports Third Quarter Financial Results
7. Cambrex Reports Third Quarter 2012 Financial Results
8. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
9. Express Scripts Reports Third Quarter Results
10. ADVENTRX Reports Third Quarter 2012 Financial Results
11. Endo Reports Third Quarter Financial Results And Updates 2012 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., ... to diagnosing and treating Autism Spectrum Disorders (ASD) announced ... Agreement with The Research Foundation for The State University ... will provide a new biomarker to identify an abnormality ... to ASD. This biomarker is expected to be available ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
(Date:9/18/2014)... YORK and PLAINSBORO, N.J. ... announced today its support of the National Hemophilia ... Care , which provides support to people with ... physical and psychosocial challenges that can impede disease ... six modules, Communication With Your Provider About ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... in patients with non-small cell lung cancer has ... multi-center, monotherapy,study of KOS-1584 in patients with measurable ... previously received only one prior,chemotherapy regimen. The primary ...
... SAN DIEGO, April 13 Researchers from ... today presented findings,showing that adding curcumin or ... preventing the growth of chemo-resistant colon cancer,cells. ... American Association,for Cancer Research (AACR) Annual Meeting ...
Cached Medicine Technology:Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 2Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 3Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 4Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
(Date:9/18/2014)... It is that time of year – ... Once again, Evensong Spa at Heidel House ... services at a special $50 rate Oct. 20 through Nov. ... Hotels & Resorts , is the only Wisconsin destination spa ... embrace health and wellness by experiencing affordable spa and wellness ...
(Date:9/18/2014)... Study after study has proven it true: exercise is ... Pennsylvania scientists suggests that exercise may have an added ... performed in a mouse model of melanoma, found that ... alone. , Joseph Libonati, an associate professor in ... of Innovative and Translational Nursing Research, was the senior ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... -- don,t worry, it,s a good thing! As scientists ... are bad. Many active enzymes and bacteria are merely ... an important part of our digestive system or can ... , an opportunistic yeast pathogen and model organism for ... personal ecosystem. However, when our immune system is stressed ...
(Date:9/18/2014)... ANGELES (September 18, 2014) The National Institutes ... funding from a four-year, $1.3 million grant to the ... in the research and development of a vaccine to ... and Methicillin-resistant Staphylococcus aureus (MRSA). , ... of the NIH awarded the grant to LA BioMed ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... Use of anesthesia providers to monitor sedation during screening ... from 2003 to 2009 in the United States, with ... not need this service, according to a new RAND ... as $1.1 billion spent annually on anesthesia services for ...
... March 20 (HealthDay News) -- Calculating the difference ... right arms might help predict a patient,s odds of ... Researchers found that people with high blood pressure whose ... higher risk of cardiovascular death over 10 years. ...
... (HealthDay News) -- The northeastern United States may see a significant ... The reason is that oak trees produced relatively few acorns ... years for the acorn crop. But the small crop means trouble ... had a boom in acorns, followed by a boom in mice. ...
... Reporter , TUESDAY, March 20 (HealthDay News) -- ... own stem cells may someday replace or reduce the ... Six months after receiving a kidney transplant, only ... stem cells experienced rejection compared with almost 22 percent ...
... failure and endocrine tumors are among the suspects causing ... relievers in your medicine cabinet be the culprit? ... Sackler Faculty of Medicine and the Sheba Medical Center, ... of hypertension, which is a major risk factor for ...
... March 20 (HealthDay News) -- Seeing a baby,s face triggers ... reward and planning movement, a finding researchers say may indicate ... Researchers observed this pattern in adults who didn,t know the ... "These adults have no children of their own. Yet images ...
Cached Medicine News:Health News:Use of anesthesia providers during GI procedures is growing, but may be unnecessary 2Health News:Blood Pressure Variance Between Arms Points to Heart Risk 2Health News:Northeast U.S. Should Brace for Spike in Lyme Disease: Expert 2Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 2Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 3Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 4Health News:Pain relievers could be spiking your blood pressure 2Health News:Infants' Faces Trigger Caregiving Impulse in Adults' Brains 2
... Flexible biopsy forceps are extremely delicate ... incompetent repair source, they can easily be ... turn, damage your endoscopes. , On the ... flexible biopsy forceps can have a virtually ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
... With our factory-quality repairs, physicians know ... why more hospitals turn to Mobile Instrument ... We offer a full line of carbide ... our four-way quality control process. You'll enjoy ...
Inquire...
Medicine Products: